Carlyle, Brighton Park Invest $200 Million in India’s Indegene
(Bloomberg) -- Indegene, a Bangalore-based global healthcare solutions company, has received $200 million of funding from Carlyle Group and Brighton Park Capital.
The transaction comprises a secondary purchase from existing shareholders and a primary capital infusion into the company, Indegene said in a statement on Tuesday. Regulatory approvals are awaited. Indegene plans to use the primary investment on mergers and acquisitions and global expansion plans.
The company, founded in 1998, helps biotech, pharmaceutical manufacturers and device makers to oversee clinical development, regulatory compliance and customer experience by digitizing operations using data and automation. It has 3,000 employees across the globe.
“Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programs,” Indegene said in the statement. Its revenue has grown at a compounded annual rate of over 25% over the past decade and its customers include 18 of the world’s top 20 biopharma companies.
©2021 Bloomberg L.P.